Fangui Sun

Fangui Sun

Auto-generated profile, based on publicly available information

Fangui Sun

Department of Biostatistics, Boston University School of Public Health Boston, MA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
LCLawreen H. Connors
Lawreen H. Connors
FSFlora Sam
Flora Sam
MSMartha Skinner
Martha Skinner
FSFrancesco Salinaro
Francesco Salinaro
FSFangui Sun
Fangui Sun
DSDavid C. Seldin
David C. Seldin
Background—: Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population. The aims of this study were to examine features of disease and to characterize outcomes in a large ATTRwt cohort. Methods and Results—: Over 20 years, 121 patients with ATTRwt were enrolled in a prospective, observational study. Median age at enrollment was 75.6 years (range, 62.6–87.8 years); 97% of patients were white. The median survival, measured from biopsy diagnosis, was 46.69 months (95% confidence interval, 41.95–56.77); 78% of deaths were attributable to cardiac causes. By Kaplan–Meier analysis, 5-year survival was 35.7% (95% confidence interval, 25–46). Impaired functional capacity (mean V o 2 max, 13.5 mL·kg −1 ·min −1 ) and atrial fibrillation (67%) were common clinical features. Multivariate predictors of reduced survival were elevated serum brain natriuretic peptide (482±337 pg/mL) and uric acid (8.2±2.6 mg/dL), decreased left ventricular ejection fraction (50% median; range, 10%–70%), and increased relative wall thickness (0.75±0.19). Conclusions—: In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atrial arrhythmias were common clinical features. Elevated brain natriuretic peptide and uric acid, decreased left ventricular ejection fraction, and increased relative wall thickness were associated with limited survival of only 35.7% at 5 years for the group as a whole. These data establish the natural history of ATTRwt, provide statistical basis for the design of future interventional clinical trials, and highlight the need for more sensitive diagnostic tests and disease-specific treatments for this disease.

24 August 2013 in Aging
Verified
Journal Article
Open access
PSPaola Sebastiani
Paola Sebastiani
HBHarold Bae
Harold Bae
FSFangui X. Sun
Fangui X. Sun
SAStacy L. Andersen
Stacy L. Andersen
EDE. Warwick Daw
E. Warwick Daw
TPThomas T Perls
Thomas T Perls
Despite evidence from family studies that there is a strong genetic influence upon exceptional longevity, relatively few genetic variants have been associated with this trait. One reason could be that many genes individually have such weak effects that they cannot meet standard thresholds of genome wide significance, but as a group in specific combinations of genetic variations, they can have a strong influence. Previously we reported that such genetic signatures of 281 genetic markers associated with about 130 genes can do a relatively good job of differentiating centenarians from non‐centenarians particularly if the centenarians are 106 years and older. This would support our hypothesis that the genetic influence upon exceptional longevity increases with older and older (and rarer) ages. We investigated this list of markers using similar genetic data from 5 studies of centenarians from the USA, Europe and Japan. The results from the meta‐analysis show that many of these variants are associated with survival to these extreme ages in other studies. Since many centenarians compress morbidity and disability towards the end of their lives, these results could point to biological pathways and therefore new therapeutics to increase years of healthy lives in the general population.

1 January 2013 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
PSPaola Sebastiani
Paola Sebastiani
FSFangui X. Sun
Fangui X. Sun
SAStacy L. Andersen
Stacy L. Andersen
JLJoseph H Lee
Joseph H Lee
MWMary Wojczynski
Mary Wojczynski
TPThomas T. Perls
Thomas T. Perls
Hypothesizing that members of families enriched for longevity delay morbidity compared to population controls and approximate the health-span of centenarians, we compared the health spans of older generation subjects of the Long Life Family Study (LLFS) to controls without family history of longevity and to centenarians of the New England Centenarian Study (NECS) using Bayesian parametric survival analysis. We estimated hazard ratios, the ages at which specific percentiles of subjects had onsets of diseases, and the gain of years of disease-free survival in the different cohorts compared to referent controls. Compared to controls, LLFS subjects had lower hazards for cancer, cardiovascular disease, severe dementia, diabetes, hypertension, osteoporosis and stroke. The age at which 20% of the LLFS siblings and probands had one or more age-related diseases was approximately 10 years later than NECS controls. While female NECS controls generally delayed the onset of age-related diseases compared with males controls, these gender differences became much less in the older generation of the LLFS and disappeared amongst the centenarians of the NECS. The analyses demonstrate extended health-span in the older subjects of the LLFS and suggest that this aging cohort provides an important resource to discover genetic and environmental factors that promote prolonged health-span in addition to longer life-span.

11 April 2017 in Fertility Research and Practice
Verified
Journal Article
Open access
PDF file
SMShruthi Mahalingaiah
Shruthi Mahalingaiah
FSFangui Sun
Fangui Sun
JCJ. Jojo Cheng
J. Jojo Cheng
ECErika T. Chow
Erika T. Chow
KLKathryn L. Lunetta
Kathryn L. Lunetta
JMJoanne Murabito, Murabito
Joanne Murabito, Murabito
Amongst women with certain types of ovulatory disorder infertility, the studies are conflicting whether there is an increased risk of long-term cardiovascular disease risk. This paper evaluates the associations of several CVD risk factors among Framingham women with self-reported infertility. Women who completed the Framingham Heart Study Third Generation and Omni Cohort 2 Exam 2 (2008–2011), and reported on past history of infertility and current cardiovascular disease status were included in this cross-sectional study. Directly measured CVD risk factors were: resting blood pressure, fasting lipid levels, fasting blood glucose, waist circumference, and body mass index (BMI). Multivariable models adjusted for age, smoking, physical activity, and cohort. Generalized estimating equations adjusted for family correlations. We performed sensitivity analyses to determine whether the association between infertility and CVD risk factors is modified by menopausal status and menstrual cycle length. Comparing women who self-reported infertility to those who did not, there was an average increase in BMI (β = 1.03 kg/m2, 95% CI: 0.18, 1.89), waist circumference (β = 3.08 in., 95% CI: 1.06, 5.09), triglycerides (β = 4.47 mg/dl, 95% CI:−1.54, 10.49), and a decrease in HDL cholesterol (β = −1.60 mg/dl, 95% CI: −3.76, 0.56). We estimated that infertile premenopausal women have an increased odds of obesity (BMI ≥ 30 kg/m2) (OR = 1.56, 95% CI: 1.11, 4.49) and diabetes (OR = 1.96, 95% CI: 0.86, 4.49). BMI and waist circumference were the most strongly correlated CVD risk factors amongst women reporting a history of infertility.

1 January 2015 in Menopause
Verified
Journal Article
Closed access
FSFangui Sun
Fangui Sun
PSPaola Sebastiani
Paola Sebastiani
NSNicole Schupf
Nicole Schupf
HBHarold Bae
Harold Bae
SAStacy L. Bs Andersen
Stacy L. Bs Andersen
TPThomas T. Perls
Thomas T. Perls
Objective This study investigated the association between maternal age at birth of last child and likelihood of survival to advanced age. Methods This was a nested case-control study using Long Life Family Study data. Three hundred eleven women who survived past the oldest 5th percentile of survival (according to birth cohort–matched life tables) were identified as cases, and 151 women who died at ages younger than the top 5th percentile of survival were identified as controls. A Bayesian mixed-effect logistic regression model was used to estimate the association between maternal age at birth of last child and exceptional longevity among these 462 women. Results We found a significant association for older maternal age, whereby women who had their last child beyond age 33 years had twice the odds for survival to the top 5th percentile of survival for their birth cohorts compared with women who had their last child by age 29 years (age between 33 and 37 y: odds ratio, 2.08; 95% CI, 1.13 to 3.92; older age: odds ratio, 1.92; 95% CI, 1.03 to 3.68). Conclusions This study supports findings from other studies demonstrating a positive association between older maternal age and greater odds for surviving to an unusually old age.

1 August 2015 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
VSVaishali Sanchorawala
Vaishali Sanchorawala
DBDina Brauneis
Dina Brauneis
ASAnthony C. Shelton
Anthony C. Shelton
SLStephen Lo
Stephen Lo
FSFangui Sun
Fangui Sun
DSDavid C. Seldin
David C. Seldin
The depth of hematologic response has been shown to correlate with survival and organ responses for patients with light chain (AL) amyloidosis. We conducted a prospective trial of 2 cycles of induction with bortezomib and dexamethasone on a twice a week schedule followed by conditioning with bortezomib and high-dose melphalan (HDM) and autologous stem cell transplantation (SCT). The objectives were hematologic responses, tolerability, and survival. Thirty-five patients were enrolled from 2010 to 2013. Of these, 30 proceeded with SCT, whereas 5 did not because of clinical deterioration during induction (n = 3) or complications after stem cell collection (n = 2). Two patients developed features of an autologous graft-versus-host disease-like syndrome post-SCT, which responded to steroids; no other unusual complications were seen. Treatment-related mortality occurred in 8.5% (3/35). Hematologic responses were achieved by 100% of the 27 assessable patients (63% complete response, 37% very good partial response [VGPR]) who completed the planned treatment. By intention-to-treat, hematologic responses occurred in 77% of patients (49% complete response, 29% VGPR). With a median follow-up of 36 months, the median overall survival and progression-free survival were not reached. In conclusion, incorporating bortezomib into induction and conditioning yielded a high rate of hematologic responses after HDM/SCT in patients with AL amyloidosis.